Irbesartan/Hydrochloorthiazide Viatris

Irbesartan, the active ingredient in Irbesartan/Hydrochloorthiazide Viatris, is an Angiotensin II receptor blocker / Thiazide diuretic presented as an oral tablet for adult use. It treats hypertension by lowering blood pressure and reducing fluid overload. GNH USA supplies Irbesartan/Hydrochloorthiazide Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control elevated blood pressure. - Essential hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. - Secondary hypertension: assists in blood‑pressure control when hypertension is caused by another condition. - Hypertension with fluid retention: combines vasodilation and diuresis to reduce volume overload and improve pressure control.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: unusual tiredness or lack of energy. - Increased urination: more frequent need to void. - Electrolyte imbalance: low potassium or sodium levels.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Blood cell abnormalities: low white blood cells or platelets. - Significant hypotension: dangerously low blood pressure.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: check regularly to ensure therapeutic targets are met. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Caution in elderly: start at lower doses and watch for orthostatic symptoms. - Avoid in severe hepatic impairment: limited data suggest increased exposure. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may alter the effect of several co‑administered medicines.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium. - ACE inhibitors: concurrent use raises the chance of hyperkalemia and renal dysfunction. - Lithium: thiazide component can raise lithium concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response and affect renal function. - Other antihypertensives: additive blood‑pressure lowering may require dose adjustments. - Loop diuretics: combined diuretic effect can lead to excessive volume depletion.